Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)
Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%
Johnson & Johnson EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Johnson & Johnson's EPS for the twelve months ending Sep 27, 2026 was $6.59, down 36.4% year over year. For fiscal 2025 it was $11.03, up 90.5% from the year before. Over ten years it grew 7.2% a year on average. The highest annual figure on record is $13.72 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $11.03 | +90.5% |
| FY2024 | Dec 29, 2024 | $5.79 | -57.8% |
| FY2023 | Dec 31, 2023 | $13.72 | +103.9% |
| FY2022 | Jan 1, 2023 | $6.73 | -13.8% |
| FY2021 | Jan 2, 2022 | $7.81 | +41.7% |
| FY2020 | Jan 3, 2021 | $5.51 | -2.1% |
| FY2019 | Dec 29, 2019 | $5.63 | +0.4% |
| FY2018 | Dec 30, 2018 | $5.61 | +1093.6% |
| FY2017 | Dec 31, 2017 | $0.47 | -92.1% |
| FY2016 | Jan 1, 2017 | $5.93 | +8.2% |
| FY2015 | Jan 3, 2016 | $5.48 | -3.9% |
| FY2014 | Dec 28, 2014 | $5.70 | +18.5% |
| FY2013 | Dec 29, 2013 | $4.81 | +24.6% |
| FY2012 | Dec 30, 2012 | $3.86 | +10.6% |
| FY2011 | Jan 1, 2012 | $3.49 | -27.0% |
| FY2010 | Jan 2, 2011 | $4.78 | +8.6% |
| FY2009 | Jan 3, 2010 | $4.40 | -3.7% |
| FY2008 | Dec 28, 2008 | $4.57 | +25.9% |
| FY2007 | Dec 30, 2007 | $3.63 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $0.09 | -95.8% |
| Q2 FY2026 | Jun 28, 2026 | $2.27 | -0.9% |
| Q1 FY2026 | Mar 29, 2026 | $2.14 | -52.9% |
| Q4 FY2025 | Dec 28, 2025 | $2.09 | +48.2% |
| Q3 FY2025 | Sep 28, 2025 | $2.12 | +91.0% |
| Q2 FY2025 | Jun 29, 2025 | $2.29 | +18.7% |
| Q1 FY2025 | Mar 30, 2025 | $4.54 | +238.8% |
| Q4 FY2024 | Dec 29, 2024 | $1.41 | -15.6% |
| Q3 FY2024 | Sep 29, 2024 | $1.11 | -89.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.93 | -1.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.34 | – |
| Q4 FY2023 | Dec 31, 2023 | $1.67 | +25.6% |
| Q3 FY2023 | Oct 1, 2023 | $10.21 | +507.7% |
| Q2 FY2023 | Jul 2, 2023 | $1.96 | +8.9% |
| Q1 FY2023 | Apr 2, 2023 | -$0.03 | -101.6% |
| Q4 FY2022 | Jan 1, 2023 | $1.33 | -24.9% |
| Q3 FY2022 | Oct 2, 2022 | $1.68 | +22.6% |
| Q2 FY2022 | Jul 3, 2022 | $1.80 | -23.4% |
| Q1 FY2022 | Apr 3, 2022 | $1.93 | -16.8% |
| Q4 FY2021 | Jan 2, 2022 | $1.77 | +172.3% |
| Q3 FY2021 | Oct 3, 2021 | $1.37 | +3.0% |
| Q2 FY2021 | Jul 4, 2021 | $2.35 | +72.8% |
| Q1 FY2021 | Apr 4, 2021 | $2.32 | +6.9% |
| Q4 FY2020 | Jan 3, 2021 | $0.65 | -56.7% |
| Q3 FY2020 | Sep 27, 2020 | $1.33 | +101.5% |
| Q2 FY2020 | Jun 28, 2020 | $1.36 | -34.6% |
| Q1 FY2020 | Mar 29, 2020 | $2.17 | +56.1% |
| Q4 FY2019 | Dec 29, 2019 | $1.50 | +33.9% |
| Q3 FY2019 | Sep 29, 2019 | $0.66 | -54.2% |
| Q2 FY2019 | Jun 30, 2019 | $2.08 | +43.4% |
| Q1 FY2019 | Mar 31, 2019 | $1.39 | -13.1% |
| Q4 FY2018 | Dec 30, 2018 | $1.12 | – |
| Q3 FY2018 | Sep 30, 2018 | $1.44 | +5.1% |
| Q2 FY2018 | Jul 1, 2018 | $1.45 | +3.6% |
| Q1 FY2018 | Apr 1, 2018 | $1.60 | -0.6% |
| Q4 FY2017 | Dec 31, 2017 | -$3.99 | -389.1% |
| Q3 FY2017 | Oct 1, 2017 | $1.37 | – |
| Q2 FY2017 | Jul 2, 2017 | $1.40 | – |
| Q1 FY2017 | Apr 2, 2017 | $1.61 | – |
| Q4 FY2016 | Jan 1, 2017 | $1.38 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?